[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-therapy-related\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-therapy-related":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,70,98,138,165,207,228,256],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100391380","proton-radiation-therapy-registry-100391380",false,"NCT04376229","Proton Radiation Therapy Registry","Inclusion Criteria:\n\n* All patients treated at the proton center.\n\nExclusion Criteria:\n\n* Any other than what is supplied in the inclusion criteria","ALL","18 Years","100 Years",{"count":19,"type":20},5000,"ESTIMATED","15 Years","OBSERVATIONAL","The Johns Hopkins Proton Therapy center is establishing a registry to capture the full 3D radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The goal is to have all patients treated at the proton center to be included in the registry to enable future comparisons of treatment outcomes to assist in understanding which patients can benefit from the use of protons.",[25],"Cancer, Therapy-Related",[27],"proton therapy","RECRUITING","2026-06-26",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2020-04-07",{"date":36,"type":20},"2040-12",{"name":38,"class":39},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","OTHER",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100627098","a-longitudinal-photo-narrative-exploration-of-hope-during-phase-12-clinical-trials-for-pediatric-cancer-100627098","NCT07444216","A Longitudinal Photo-Narrative Exploration of Hope During Phase 1\u002F2 Clinical Trials For Pediatric Cancer","Sharing Hope: A Longitudinal Photo-Narrative Exploration of Hope During Phase 1\u002F2 Clinical Trials For Pediatric Cancer","Inclusion Criteria:\n\nPatient participants must\n\n* Be 12 to 25 years of age.\n\nAND\n\n* Have a primary cancer diagnosis that is relapsed, refractory, or without curative standard-of-care options as follows:\n\n  * 'Relapsed' disease is defined as disease recurrence following a prior complete or partial response to initial therapy.\n  * 'Refractory' disease is defined as failure to achieve remission or response with standard upfront therapy.\n  * Diagnoses will be considered 'without curative standard of care options' if there is no evidence-based curative treatment regimen or where standard therapies offer only palliative or non-curative intent (based on the assessment of the primary attending or division tumor board).\n\nAND\n\n* Be enrolled OR planning to enroll in a phase 1 or phase 2 trial for cancer-directed therapy.\\* Patients will remain eligible until 4 weeks after they begin trial therapy, after which they are no longer eligible unless they subsequently enroll on a different clinical trial.\n\nCaregiver participants must\n\n* Be a parent or primary caregiver to a child of any age who\n\n  * Has a primary cancer diagnosis that is relapsed, refractory, or without curative standard-of-care options\n\nAND\n\n* Is enrolled OR planning to enroll on a phase 1 or phase 2 trial for cancer-directed therapy.\\* Parents will remain eligible until 4 weeks after their child begins trial therapy, after which they are no longer eligible unless their child subsequently enrolls on a different clinical trial.\n\n  * Be ≥ 18 years of age or legally emancipated\n\nMedical clinician participants (Primary Objectives 1-2) must\n\n* Be a physician, advanced practice provider, or nurse providing direct patient care to the patient participant and\u002For to the child of the caregiver participant.\n\nPsychosocial clinician participants (Primary Objective 2 only) must\n\n* Be a psychosocial clinician (e.g., social worker, psychologist, chaplain, child life specialist, music therapist, cultural navigator, etc.)\n\nAND\n\n* Provide direct or consultative care to pediatric or adolescent\u002Fyoung adult patients with relapsed, refractory, or high-risk cancer and\u002For their families.\n\nExclusion Criteria:\n\nPatients, Caregivers, and Clinicians will be excluded if they:\n\n* Do not meet inclusion criteria.\n* Decline, refuse, or are unwilling to participate.\n* Are a minor without a legal guardian available or willing to provide informed consent.\n* Lack the cognitive, communicative, or physical capacity to meaningfully participate in a photo-narrative interview, as determined by the research team in consultation with the patient, caregiver, and primary oncology team. This includes, but is not limited to, individuals with profound neurocognitive impairment, non-responsiveness, or other conditions that preclude the ability to engage in basic reflection, expression, or shared conversation about images.","12 Years",{"count":50,"type":20},100,"The purpose of this study is to find better ways to help support families in their hopes during cancer treatment.\n\nPrimary Objective\n\n* To characterize themes related to how patients and parents\u002Fcaregivers narrate their experience of 'hope' when receiving cancer therapy on a phase 1\u002F2 clinical trial, with a focus on whether, why, when, and how patients' and caregivers' hopes adapt to changing circumstances.\n* To engage patients, caregivers, and clinicians in focus groups to identify strengths, weaknesses, opportunities, and threats to hope during phase 1\u002F2 clinical trial participation and facilitate the co-design of a stakeholder-driven supportive intervention related to hope based on focus group recommendations.\n\nSecondary Objective\n\n* To describe health care provider perspectives on patient and family hope and goal-care concordance in the context of phase 1\u002F2 clinical trials.",[25],[54,55,56,57,58,59],"Photo-elicitation","Patient Participants","Parents\u002FCaregivers","Clinicians","Interviews","Focus Groups","2026-04-24",{"date":62,"type":32},"2026-04-28",{"date":64,"type":32},"2026-04-09",{"date":66,"type":20},"2030-03",{"name":68,"class":39},"St. Jude Children's Research Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":69},"100491840","exercise-to-regain-stamina-and-energy-the-exergise-study-100491840","NCT05684367","Exercise to ReGain Stamina and Energy (The EXERGISE Study)","Center-Based and Home-Based Walking Exercise Intervention to Reduce Fatigue in Older Breast Cancer Survivors","Inclusion Criteria:\n\n* Consent to participate in the study\n* Age ≥ 60 years old\n* Had stage I-III invasive breast cancer\n* The cancer is diagnosed in 2021 or 2022\n* Completed adjuvant therapy for at least 3 months but no more than 1 year\n* Willingness to participate in all study procedures\n* Had at least moderate-level fatigue (defined as raw score ≥ 8 on the PROMIS Measure)\n\nExclusion Criteria:\n\n* Failure to provide informed consent\n* Current involvement in rehabilitation program\n* Absolute contraindications to exercise training\n* Significant cognitive impairment\n* Progressive, degenerative neurologic disease\n* Hip fracture, hip or knee replacement, or spinal surgery within past 4 months\n* Other significant comorbidities that may impair ability to participate in the exercise intervention\n* Pregnant\n* Regular consumption of nicotinamide riboside supplement\n* Simultaneous participation in other interventional studies\n* Had no or very mild fatigue (defined as raw score ≤7 in PROMIS)\n* Diagnosis of any of the following medical conditions in past three years (coronary heart disease, angina, heart attack, heart failure, stroke, high blood pressure, chronic obstructive pulmonary disease, chronic bronchitis, arthritis, diabetes mellitus, and chronic kidney disease), as measured by Behavioral Risk Factor Surveillance System\n* Receipt of any oral or intravenous antibiotic 4 weeks prior to screening\n* Receipt of any probiotics within 4 weeks of screening\n* History of active treatment for HIV, hepatitis B, or hepatitis C infection\n* Positive stool cultures for enteric pathogens, including Clostridium difficile\n* Excessive alcohol use (i.e., \\> 14 drinks\u002Fweek) or alcohol abuse (i.e., \\> 5 drinks\u002Fday for males or \\> 4 drinks\u002Fday for females)\n* Other substance abuse within the past 3 years\n* Smoking history in past 3 years","FEMALE","60 Years","105 Years",{"count":81,"type":20},24,"INTERVENTIONAL",[84],"NA","About 20%-70% of breast cancer survivors experience fatigue after cancer therapy. Because epidemiologic evidence shows that old age is a risk factor for fatigue in adults with cancer history, older breast cancer survivors suffer from even more fatigue than younger survivors. The purpose of this study is to test types of walking exercise interventions and their ability to reduce fatigue in older breast cancer survivors.",[87,88,25],"Fatigue","Breast Cancer","2026-02-03",{"date":91,"type":32},"2026-02-05",{"date":93,"type":32},"2023-11-29",{"date":95,"type":20},"2026-08",{"name":97,"class":39},"University of Florida",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":107,"conditions":108,"keywords":118,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100374121","canadian-cancers-with-rare-molecular-alterations-carma---basket-real-world-observational-study-bros-100374121","NCT04151342","CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)","CARMA-BROS","Inclusion Criteria:\n\n* Patients ≥ 18 years at cancer diagnosis\n* Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations\n* Accessible\u002Favailable molecular testing reports\u002Fdocumentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \\[PCR\\] based next generation sequencing \\[NGS\\], immunohistochemistry \\[IHC\\], fluorescence in situ hybridization \\[FISH\\], liquid biopsy)\n* Canadian resident received follow-up for cancer care in Canada or is currently receiving\u002Fplanning follow-up for cancer care to occur in Canada at time of enrollment\n\nExclusion Criteria:\n\n* Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent",{"count":106,"type":20},5500,"This study will collect data on Canadian cancer patients that have uncommon\u002Frare changes in their tumours, such as alterations\u002Frearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.",[109,110,111,25,112,113,114,115,116,117],"Cancer","Malignancies Multiple","Malignant Solid Tumor","Molecular Sequence Variation","Genetic Alteration","Gene Fusion","Receptor Tyrosine Kinase Gene Mutation","RTK Family Gene Mutation","Ras (Kras or Nras) Gene Mutation",[119,120,121,122,123,124,125,126,127],"observational study","cancer","cancer therapies","molecular alterations","real-world evidence","real-world data","tyrosine kinase inhibitors","ambispective","ras GTPase inhibitors","2025-11-25",{"date":130,"type":32},"2025-12-03",{"date":132,"type":32},"2020-01-17",{"date":134,"type":20},"2029-12",{"name":136,"class":39},"University Health Network, Toronto",27,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":82,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":69},"100592852","the-effect-of-survival-response-and-microbiota-change-in-different-therapy-under-probiotic-supplement-100592852","NCT06998823","The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement","The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement (Clostridium Butyricum) in Patient With Malignant Tumor","Inclusion Criteria:\n\n1. age≧20\n2. participants with cancer therapy and agree to sign informed consent\n3. Cancer confirmed by clinical or pathological diagnosis\n\nExclusion Criteria:\n\n1. age\\\u003C20\n2. Pregnant or breastfeeding women","20 Years",{"count":147,"type":20},120,[84],"Probiotics are a group of viable microorganisms including bacteria and yeasts that if consumed in sufficient amounts, may afford health benefits to the host. The major advantage of probiotic administration is its ability to maintain gut microbial homeostasis, reduce pathogenic microorganisms in the GI tract, and restores homeostasis of intestinal microorganisms. Moreover, by modulating microbiota and immune responses, decreasing bacterial translocation, promoting the function of the gut barrier, inducing anti- inflammatory properties, triggering anti-pathogenic activity, and decreasing tumor development and metastasis, probiotics might contribute to the prevention and treatment of GI cancers and lung cancer. Considering the potential roles of Helicobacter pylori (H. pylori) in the initiation of colorectal and gastric cancers, the possible properties of probiotics against GI neoplasm in humans have been investigated in relation to their suppressive effects on H. pylori. The gut microbiota also has proved to in the response and resistance to immunotherapy. By triggering immune activity, probiotics, as functional dietary supplements, may mitigate neoplastic predisposition and development of GI cancers. Clostridium butyricum is a spore-forming bacillus named for its capacity to produce high amounts of butyric acid and is found in soil. Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea, and anti- microbial-associated diarrhea in Japan and China. Clostridium butyricum increases beneficial bacteria, especially lactobacilli and bifidobacteria. Bifidobacterium promotes antitumor immunity and facilitates efficacy of antitumor treatment. The antitumor treatments are differed to three types: immune checkpoint blockade, target therapy and chemotherapy. Thus, investigators hypothesized that probiotic Clostridium butyricum therapy (CBT) may enhance the therapeutic efficacy of anti-tumor therapy through the modulation of gut microbiota. Investigators will discuss the different kinds of anti-tumor effect in survival and response after probiotic supplement.",[151,25],"Probiotics",[151,153,154,155],"Immunotherapy","Targeted Therapy","Chemotherapy","2025-05-22",{"date":158,"type":32},"2025-05-31",{"date":160,"type":32},"2024-03-20",{"date":162,"type":20},"2026-11-08",{"name":164,"class":39},"Chang Gung Memorial Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":77,"minAge":16,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":82,"phases":174,"briefSummary":176,"conditions":177,"keywords":189,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":40},"100474986","phase-4-sacubitrilvalsartan-in-primary-prevention-of-the-cardiotoxicity-of-systematic-breast-cancer-treatment-mainstream-100474986","NCT05465031","Sacubitril\u002FValsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","Sacubitril\u002FValsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent","Inclusion Criteria:\n\n* Written informed consent\n* Female gender, aged 18 years and over\n* Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (Estrogen receptor - ER, Progesterone receptor - PR, Human epidermal growth factor receptor 2 - HER2, Kiel - Ki67)\n* Ability to take oral medication and willingness to adhere to the planned regimen\n* Tumor grade IA-IIIC or oligometastatic grade IV\n* Radical treatment plan including surgery\n* Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and\u002For anti-HER2 drugs\n* Eastern Cooperative Oncology Group (ECOG) 0-2 general status\n* LVEF ≥ 50% as assessed by echocardiography\n* Sinus rhythm\n\nExclusion Criteria:\n\n* Prior anthracycline-based chemotherapy and\u002For thoracic radiotherapy (prior to diagnosis of the cancer being the present cause of therapy)\n* Clinically relevant HF (NYHA II-IV)\n* Myocardial infarction (MI) within the last \\\u003C 3 months\n* Symptomatic hypotension or systolic blood pressure (SBP) \\\u003C 90 mmHg\n* Significant valvular disease, symptomatic coronary artery disease (CCS\\>2), significant atrioventricular (AV) block, symptomatic sinus node dysfunction\n* Expected survival \\\u003C12 months\n* Glomerular filtration rate (GFR) \\\u003C30 ml\u002Fmin\u002F1.73 m2 (screening visit)\n* K+\\>5.5mmol\u002FL (screening visit)\n* Contraindications to angiotensin converting enzyme inhibitor (ACE-I)\u002Fangiotensin II receptor blocker (ARB) or LCZ696 if not listed among criteria\n* Active untreated liver disease\n* Pregnancy\n* Conditions\u002Fcircumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug\u002Falcohol dependence, poorly controlled mental illness)",{"count":173,"type":20},600,[175],"PHASE4","Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020. Although the modern treatment strategies, based on the complex care, which consists of surgery, radiotherapy, hormone therapy, and targeted chemotherapy directed at specific cancer molecules have substantially reduced the risk of death due to breast cancer, their wide adoption results in the wider prevalence of cardiotoxicity, defined as either symptomatic heart failure, or asymptomatic contractile dysfunction. The occurrence of cardiotoxicity induced by anti-cancer therapies is estimated at 5-15%, and its development is the primary cause of therapy termination, which significantly reduces the probability of the efficacy of treatment. Several attempts have been made to determine the efficacious preventive strategy, which could diminish the risk of cancer-therapy induced cardiotoxicity. The results of the prior studies indicated a trend towards lower risk of troponin elevation, or left ventricular contractile dysfunction with the introduction of drugs interfering with the renin-angiotensin-aldosterone (RAA) axis, which constitute the primary treatment modality in heart failure with reduced ejection fraction (HFrEF). Sacubitril\u002Fvalsartan, the novel therapeutic agent, has been demonstrated to significantly improve prognosis in patients with HFrEF. Prior retrospective, small, single-center studies have shown that treatment with sacubitril\u002Fvalsartan may reduce the risk of cancer-therapy induced cardiotoxicity, or reverse contractile dysfunction caused by anti-cancer therapy. However, no large randomized data confirmed these findings.\n\nTherefore, the Sacubitril\u002FValsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent) study, has been designed to verify, whether the preventive use of sacubitril\u002Fvalsartan administered in the doses recommended in patients with HFrEF in breast cancer patients undergoing adjuvant chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will reduce the incidence of cardiotoxicity defined as impaired left ventricular systolic function on transthoracic echocardiography (TTE). In the trial, a total of 480 patients with histologically confirmed breast cancer, who are eligible for chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will undergo 1:1 randomization to either preventive treatment with sacubitril\u002Fvalsartan or placebo. The patients will be followed for 24 months, and will have repetitive efficacy and safety examinations, including echocardiography, MRI (optionally), electrocardiography including 24-h Holter monitoring, blood tests, functional capacity tests and quality of life assessment.",[88,178,179,180,181,182,183,184,185,186,25,187,188],"Neoplasm, Breast","Breast Diseases","Antihypertensive Agents","Sacubitril\u002FValsartan","Angiotensin II Type 1 Receptor Blockers","Angiotensin Receptor Antagonists","Molecular Mechanisms of Pharmacological Action","Heart Failure","Cardiac Toxicity","Cancer Therapy-Related Cardiac Dysfunction","Cardiotoxicity",[190,181,191,192,193,88,188,194,195,196,197],"LCZ696","Magnetic Resonance Imaging","Echocardiography","Cardio-oncology","Anthracyclines","Trastuzumab","Heart failure","Cardioprotection","2025-03-11",{"date":200,"type":32},"2025-03-14",{"date":202,"type":32},"2024-04-17",{"date":204,"type":20},"2029-02",{"name":206,"class":39},"Silesian Centre for Heart Diseases",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":218,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100545018","a-multicentre-real-world-study-of-heptapopal-ethanolamine-tablets-in-concurrentsequential-radioimmunoinduced-thrombocytopenia-100545018","NCT06376435","A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent\u002FSequential Radioimmunoinduced Thrombocytopenia","Inclusion Criteria:\n\n* Understand the research procedure and voluntarily sign the informed consent to participate in the study\n* Subjects ≥18 years of age receiving synchronous\u002Fsequential chemotherapeutic therapy\n* Patients with platelet count ≤100×109\u002FL or platelet count decrease ≥ 50×109\u002FL or platelet count \\> 100×109\u002FL but need to be prophylaxis with hexapopethanolamine tablets\n* Researchers believe that subjects need to be treated with hexapopal.\n\nExclusion Criteria:\n\n* The subjects are conducting clinical intervention studies\n* Patients with known or expected allergy or intolerance to the active ingredient or excipient of hexapopar\n* Pregnant or lactating women\n* Other conditions deemed unsuitable for inclusion in the study by the researcher.","75 Years",{"count":215,"type":20},500,"The objective of this study was to observe and evaluate the efficacy and safety of hexapopal ethanolamine tablets in the treatment of synchronous\u002Fsequential radioimmunoinduced thrombocytopenia in the real world.\n\nThe subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia.\n\nThis study will retrospectively and prospectively collect real-world data related to investigational drugs, and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia. The study included a screening period (no more than one week) and a treatment period (at least two cycles).Participants meeting protocol inclusion criteria were defined as having platelet values \\\u003C 100×109\u002FL during radioimmunotherapy.",[25],"NOT_YET_RECRUITING","2024-04-18",{"date":221,"type":32},"2024-04-19",{"date":223,"type":20},"2024-04-20",{"date":225,"type":20},"2026-07-01",{"name":227,"class":39},"Hebei Medical University Fourth Hospital",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":213,"enrollmentInfo":235,"targetDuration":4,"studyType":82,"phases":237,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":69},"100500501","phase-3-postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna-100500501","NCT05797077","Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA: a Multicenter, Randomized, Controlled, Phase III Clinical Trial.","Inclusion Criteria:\n\n1. Both males and females, aged 18-75 years;\n2. Patients with liver metastatic colorectal cancer who have undergone R0 resection based on MDT evaluation (including patients whose metastases have been treated with ablation achieving similar R0 resection effect);\n3. Postoperative ctDNA-positive patients;\n4. ASA grade \\\u003C IV and\u002For ECOG performance status score ≤ 2;\n5. Participants must have a full understanding of the study and voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases to other sites, including the pelvis, ovaries, peritoneum, etc.\n2. Patients with a history of other malignant tumors.\n3. Patients with severe liver or kidney dysfunction, cardiorespiratory dysfunction, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy.\n4. Patients who are allergic to any component of the study.\n5. Patients who have received other tumor-related investigational drug treatments.\n6. Patients with severe uncontrolled recurrent infections or other severe uncontrolled accompanying diseases.\n7. Patients with other factors that may affect the study results or lead to early termination of the study, such as alcoholism, drug abuse, other serious diseases requiring comprehensive treatment (including mental illness), and severe laboratory abnormalities.\n8. Patients with a history of severe mental illness.\n9. Pregnant or lactating women.\n10. Patients who, in the opinion of the researchers, have other clinical or laboratory conditions that make them unsuitable for participation in the study.",{"count":236,"type":20},346,[238],"PHASE3","The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.",[241,242,243,25],"Colorectal Cancer","Liver Metastases","Circulating Tumor Cell",[241,242,245,246],"ctDNA","maintenance therapy","2023-04-03",{"date":249,"type":32},"2023-04-04",{"date":251,"type":32},"2023-02-20",{"date":253,"type":20},"2031-02-20",{"name":255,"class":39},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":145,"studyType":22,"phases":4,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100450934","proton-therapy-medical-registry-100450934","NCT05151952","Proton Therapy Medical Registry","Inclusion Criteria:\n\n* All patients treated at the proton center\n\nExclusion Criteria:\n\n* Any other than what is supplied in the inclusion criteria",{"count":263,"type":20},6000,"Clínica Universidad de Navarra Proton Therapy Unit is establishing a registry to capture the full radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The objectives are parameters prescribed and to have all patients treated at the proton therapy unit to be included in the registry to enable future analysis of treatment outcomes to assist in understanding, which patients can benefit from the use of protons.",[25],[267],"Proton therapy Additional relevant MeSH terms: Neoplasms, Secondary Primary Neoplasms, Cancer","2021-11-25",{"date":270,"type":32},"2021-12-09",{"date":272,"type":32},"2020-04-01",{"date":274,"type":20},"2050-04-01",{"name":276,"class":39},"Clinica Universidad de Navarra, Universidad de Navarra",2]